Table 2.

Efficacy at day 28, day 42 and day 56 (trial 1 only) expressed as percentage with ACPR

	DP	AS + SP T1	AS + SP T2	AS + SP T3
N (enrolled)	59	61	100	83
d28
Successful follow-up	53	57	97	78
Reinfection	0	0	0	0
Analysed	53	57	97	78
Recrudescence	0	0	1	0
ACPR % (95 % CI)	100 (93.2–100)	100 (93.7–100)	99.0 (94.4–99.8)	100 (95.3–100)
d42
Successful follow-up	52	56	97	77
Recurrence: reinfection	0	0	3	1
Recurrence: unknown genotype	0	0	2	0
Analysed	52	56	92	76
Recrudescence	0	0	2	0
ACPR (95 % CI)	100 (93.1–100)	100 (93.6–100)	97.8 (92.4–99.4)	100 (95.2–100)
d56
Successful follow-up	50	52
Recurrence: reinfection	0	0
Recurrence: unknown genotype	0	0
Analysed	50	52
Recrudescence	0	0
ACPR (95 % CI)	100 (92.9–100)	100 (93.1–100)

Successful follow-up indicates patients seen up to and including the corresponding time point. Recurrences due to reinfection and one patient in the AS + SP arm with P. vivax infection at d28 were censored from analysis